West Announces Fourth-Quarter and Full-Year 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
West Pharma (WST) Tops Q4 EPS by 22c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus
February 18, 2021 6:21 AM ESTWest Pharma (NYSE: WST) reported Q4 EPS of $1.34, $0.22 better than the analyst estimate of $1.12. Revenue for the quarter came in at $580.2 million versus the consensus estimate of $543.67 million.
Fourth-Quarter and Full-Year 2020 Summary (comparisons to prior-year period)
Fourth-quarter 2020 net sales of $580.2 million grew 23.3%; organic sales growth was 19.8%. Full-year 2020 net sales of $2.147 billion grew 16.7%; organic sales growth was 16.3%.Fourth-quarter 2020 reported-diluted EPS of $1.29 increased 53.6%. Full-year 2020 reported-diluted EPS of $4.57 increased 42.4%.Fourth-quarter 2020 adjusted-diluted EPS of $1.34 increased 63.4%. Full-year 2020 adjusted-diluted EPS of $4.76 increased 46.9%."We had a successful 2020 with tremendous execution, dedication and... More
